Skip to content

Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04785443
Acronym
HYPOCAAVI
Enrollment
242
Registered
2021-03-05
Start date
2021-06-22
Completion date
2027-06-22
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Diseases

Keywords

Hypocalcemia, Hypoparathyroidism, Angiography

Brief summary

* Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months. * Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting in a significant deterioration in quality of life. * The intraoperative use of indocyanine green (ICG) angiography has recently been described as a reliable means of detecting parathyroidism and predicting the risk of postoperative hypoparathyroidism. * This use could prove to be a way to preserve parathyroid in vivo and thus reduce post-operative hypoparathyroidism rates.

Detailed description

Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It is most often transient but can sometimes be permanent when it persists for more than 6 months after surgery. The rates are variable, of the order of 32% for transient hypoparathyroidism and 1% for definitive hypoparathyroidism. Untreated permanent hypoparathyroidism is the source of many complications in general and therefore requires lifelong replacement therapy. The result is a significant deterioration in quality of life. The mechanisms responsible for hypoparathyroidism during thyroidectomy are direct damage to the parathyroid glands, involuntary excision of these glands, and devascularization of these glands. The detection of parathyroid glands and the prevention of hypoparathyroidism after thyroidectomy therefore represents a major challenge. The intraoperative use of indocyanine green angiography has recently been described as a reliable means of detecting parathyroid and predicting the risk of postoperative hypoparathyroidism. In addition, prior studies and intraoperative observations suggest that indocyanine green angiography during thyroid surgery may be a means of preserving parathyroid in vivo and thus reducing post-operative hypoparathyroidism rates.

Interventions

DRUGICG

During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection. Patients will then be followed during 6 months.

PROCEDUREControl group

During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes. Patients will then be followed during 6 months.

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Simple blind (only participant)

Intervention model description

Monocentric, comparative, randomized, single-blind, controlled trial against the reference method

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient having to undergo a total thyroidectomy * Signed consent * Patient beneficiary of a social security regimen

Exclusion criteria

* Minor patient under 18 years old * Major patient protected by law or unable to give informed consent * Pregnant or breastfeeding woman * Thyroidectomy totalization * History of thyroid or parathyroid surgery * Participation refusal * Known allergy to ICG * Woman of child-bearing age not using adequate method of contraception

Design outcomes

Primary

MeasureTime frameDescription
Compare the frequency of albumin-corrected hypocalcemia (blood sugar below 2 mmol/L, a sign associated with hypoparathyroidism) postoperatively between the ICG group and the control group.Day 2Frequency of albumin-corrected hypocalcemia (≤2 mmol/L) within 48 hours postoperatively.

Secondary

MeasureTime frameDescription
Evaluate the contribution of ICG angiography in the modification of the rate of definitive hypoparathyroidism after total thyroidectomy.Day 8, Month 1 and Month 6Occurrence (yes/no) of albumin-corrected (\<2mmol/L) postoperative hypocalcemia at D8, M1 and M6
Determine the contribution of indocyanine green angiography (ICG) during the total thyroidectomy procedure for in vivo detection and preservation of parathyroid glands.Day 0Modification (yes/no) of the surgical procedure by improving the detection of parathyroids or their vascularization during thyroidectomy with the use of indocyanine green angiography.
To evaluate the contribution of indocyanine green angiography in the prediction of postoperative hypocalcemia.Day 0Intraoperative parathyroid vitality score (0=devascularized parathyroid gland to 2 = vascularized thyroid gland) when using indocyanine green angiography.
To determine the interest of indocyanine green angiography (ICG) in the prediction of hypoparathyroidism after total thyroidectomy.Day 1 and Day 2Occurrence (yes/no) of hypo parathormone at D1 and D2 postoperatively (\<10ng/L).
Compare the frequency of postoperative hypocalcemia, according to its grade (mild, moderate and deep), between the ICG group and the control group.D1 and D2Frequency of mild (asymptomatic and \>1.7mmol/l), moderate (symptomatic and \>1.7mmol/l) and profound (\<1.7mmol/l) hypocalcemia within 48 hours postoperatively.
Evaluate the tolerance of indocyanine green.Day 1, Day 2, Day 10Occurrence of an adverse event related to the injection of indocyanine green.

Countries

France

Contacts

CONTACTJean-Christophe LECLERE, PhD
jean-christophe.leclere@chu-brest.fr0298223630
PRINCIPAL_INVESTIGATORJean-Christophe LECLERE, PhD

CHRU de Brest

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026